Anti-CD19 Reference Antibody (tafasitamab)
- Product Code: 139861
| Molecular Weight: | Molecular Formula: | ||
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20℃ |
Product Description:
Used in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It targets CD19, a protein found on the surface of B-cells, including malignant B-cells. By binding to CD19, it activates immune-mediated cell killing, including antibody-dependent cellular cytotoxicity (ADCC). Often used in combination with lenalidomide to enhance therapeutic effect. Also serves as a reference standard in bioanalytical assays and drug development for evaluating CD19-targeting therapeutics.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 50μg | 10-20 days | $214.39 |
+
-
|
Anti-CD19 Reference Antibody (tafasitamab)
Used in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It targets CD19, a protein found on the surface of B-cells, including malignant B-cells. By binding to CD19, it activates immune-mediated cell killing, including antibody-dependent cellular cytotoxicity (ADCC). Often used in combination with lenalidomide to enhance therapeutic effect. Also serves as a reference standard in bioanalytical assays and drug development for evaluating CD19-targeting therapeutics.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
$0.00
$0.00
Total :